| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA355944
Max Phase: Preclinical
Molecular Formula: C26H22N2O5
Molecular Weight: 442.47
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: Cc1c(C(=O)C(N)=O)c2c(OCC(=O)O)cccc2n1Cc1cccc(-c2ccccc2)c1
Standard InChI: InChI=1S/C26H22N2O5/c1-16-23(25(31)26(27)32)24-20(11-6-12-21(24)33-15-22(29)30)28(16)14-17-7-5-10-19(13-17)18-8-3-2-4-9-18/h2-13H,14-15H2,1H3,(H2,27,32)(H,29,30)
Standard InChI Key: CXAFWBHDYGONMZ-UHFFFAOYSA-N
Associated Targets(Human)
PLA2G2A Tchem Phospholipase A2 group IIA (1079 Activities)
PLA2G1B Tchem Phospholipase A2 group 1B (720 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
PLA2G1B Phospholipase A2 group 1B (227 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 442.47 | Molecular Weight (Monoisotopic): 442.1529 | AlogP: 3.80 | #Rotatable Bonds: 8 |
| Polar Surface Area: 111.62 | Molecular Species: ACID | HBA: 5 | HBD: 2 |
| #RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 3.54 | CX Basic pKa: | CX LogP: 3.90 | CX LogD: 0.53 |
| Aromatic Rings: 4 | Heavy Atoms: 33 | QED Weighted: 0.32 | Np Likeness Score: -0.73 |
References
| 1. Draheim SE, Bach NJ, Dillard RD, Berry DR, Carlson DG, Chirgadze NY, Clawson DK, Hartley LW, Johnson LM, Jones ND, McKinney ER, Mihelich ED, Olkowski JL, Schevitz RW, Smith AC, Snyder DW, Sommers CD, Wery JP.. (1996) Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides., 39 (26): [PMID:8978844] [10.1021/jm960487f] |
| 2. Robello M, Barresi E, Baglini E, Salerno S, Taliani S, Settimo FD.. (2021) The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities., 64 (7.0): [PMID:33764065] [10.1021/acs.jmedchem.0c01808] |
Source
Source(1):